ALKS — Alkermes plc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1520262 ·
Last close
$45.45
Market Cap
$7.64B
52W High
$55.67
52W Low
$27.00
ADV30
1,784,120
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 480,132,000 385,912,000 36,592,000 16,287,000 4,435,523,000 631,314,000 2,570,802,000
Jun 2026 — — — — — — —
Mar 2026 392,911,000 331,333,000 -48,280,000 -66,480,000 4,258,076,000 351,551,000 2,506,545,000
Dec 2025 384,547,000 338,338,000 58,104,000 49,341,000 2,486,993,000 388,570,000 667,698,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$199,475,000
Investing CF
$-1,741,401,000
Financing CF
$1,492,064,000
CapEx
$-37,822,000
Dividends Paid
—
Buybacks
$-27,696,000
EPS Diluted TTM
$-0.02
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-784,486,000
Inventory
$261,098,000
Receivables
$459,090,000
ST Investments
$124,150,000
EBIT TTM
$174,653,000
Pretax Income TTM
$113,933,000
Interest Exp TTM
$60,720,000
Analysts
19

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,753,598,976
EBITDA
$281,691,008
Free Cash Flow
$230,842,368
Enterprise Value
$8,528,815,616
Total Cash
$755,464,000
Total Debt
$1,571,080,960
Shares Out
168,043,540
Trailing EPS
$-0.01
Book Value
$11.10
ROE
-0.0%
ROA
3.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,475,899,000 253,956,000 241,664,000 2,486,993,000 667,698,000 1,819,295,000 520,754,000
Dec 2024 1,557,632,000 420,636,000 367,070,000 2,055,567,000 590,590,000 1,464,977,000 439,124,000
Dec 2023 1,663,405,000 414,122,000 355,757,000 2,136,223,000 933,537,000 1,202,686,000 401,353,000
Dec 2022 1,111,795,000 -6,089,000 -158,267,000 1,963,978,000 920,225,000 1,043,753,000 21,044,000

TTM Snapshot

Revenues TTM
$1,667,652,000
NetIncome TTM
$66,123,000
OpCashFlow TTM
—
Assets (Latest)
$4,393,125,000
Forward EPS
$1.35

Max Pain — expiry 2026-12-18

max pain strike: $42.00 · spot: $46.85 · call oi: 4,580 · put oi: 1,449
Expected Move to 2026-12-18: ±$5.50 (11.74%) — implied range $41.35 – $52.35 · ATM straddle on $47.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CORT CORCEPT THERAPEUTICS INC $7.67B $70.07 —
AMRX Amneal Pharmaceuticals, Inc. $7.36B $21.12 —
PTGX Protagonist Therapeutics, Inc $8.07B $124.67 —
RYTM RHYTHM PHARMACEUTICALS, INC. $8.08B $116.61 —
CYTK CYTOKINETICS INC $7.20B $51.65 —

News headlines (Yahoo Finance, 1h cache)

Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
2026-11-16 09:12 · Yahoo
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
2026-11-05 12:00 · Yahoo
Alkermes (ALKS) Stock Could Be Overvalued Following ALKS 7290 Trial Launch
2026-11-04 12:15 · Yahoo
Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ...
2026-11-04 03:04 · Yahoo
Alkermes (ALKS) Q3 2026 Earnings Call Transcript
2026-11-03 21:28 · Yahoo
Alkermes to Present at Upcoming Investor Conferences
2026-11-03 21:00 · Yahoo
What Alkermes (ALKS) Said on Its Q3 Earnings Call
2026-11-03 18:14 · Yahoo
Alkermes plc Q3 2026 Earnings Call Summary
2026-11-03 17:49 · Yahoo
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
2026-11-03 13:30 · Yahoo
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
2026-11-03 12:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.